Discovery of CJ-2360 as a Potent and Orally Active Inhibitor of Anaplastic Lymphoma Kinase Capable of Achieving Complete Tumor Regression-Reference-Cited by-同舟云学术

Discovery of CJ-2360 as a Potent and Orally Active Inhibitor of Anaplastic Lymphoma Kinase Capable of Achieving Complete Tumor Regression

Published:2020-11-13 Issue:22 Volume:63 Page:13994-14016
ISSN:0022-2623
Container-title:Journal of Medicinal Chemistry
language:en
Short-container-title:J. Med. Chem.

Author:

Chen Jianyong¹²,Zhou Yunlong²,Dong Xuyuan¹,Liu Liu¹,Bai Longchuan¹,McEachern Donna¹,Przybranowski Sally¹,Yang Chao-Yie¹^ORCID,Stuckey Jeanne³,Li Xiaoqin⁴,Wen Bo⁴,Zhao Ting⁴,Sun Siwei⁴,Sun Duxin⁴,Jiao Lingling²,Jing Yu²,Guo Ming²,Yang Dajun²,Wang Shaomeng¹^ORCID

Affiliation:

1. Rogel Cancer Center and Departments of Internal Medicine, Pharmacology, and Medicinal Chemistry, University of Michigan, Ann Arbor, Michigan 48109, United States

2. Ascentage Pharma (Jiangsu), Medical City Avenue, QB3 Building First Floor, Taizhou, Jiangsu Province 225300, China

3. Life Sciences Institute, University of Michigan, Ann Arbor, Michigan 48109, United States

4. Department of Pharmaceutical Sciences, College of Pharmacy, University of Michigan, Ann Arbor, Michigan 48109, United States

Funder

Ascentage Pharma Group

Publisher

American Chemical Society (ACS)

Subject

Drug Discovery,Molecular Medicine

Link

https://pubs.acs.org/doi/pdf/10.1021/acs.jmedchem.0c01550

Reference36 articles.